31 August 2018
Advanced Medical Solutions Group plc
(“AMS” or the “Company” or the “Group”)
Application for Admission
Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that an application has been made to the London Stock Exchange for the admission of a total of 8,023,268 ordinary shares of 5 pence each (the “Ordinary Shares”) to trading on AIM.
All of the Ordinary Shares to which this application relates, have been previously issued and allotted under various employee share schemes. As a result, following the admission of these Ordinary Shares, there will be no change to the Company’s current issued share capital, which consists of 213,442,312 Ordinary Shares with voting rights.
Further, AMS announces that an application has been made to the London Stock Exchange for the block listing of securities in respect of a total of 4,476,264 ordinary shares of 5 pence each (the “New Ordinary Shares”) to be admitted to trading on AIM.
The block listing application relates to New Ordinary Shares to be issued from time to time pursuant to the exercise of share options under the Company’s existing schemes as follows:
|
Scheme |
No. of New Ordinary Shares |
|
Deferred Share Bonus Scheme |
804,569 |
|
Enterprise Management Incentive Scheme |
43,172 |
|
Company Share Option Plan |
439,808 |
|
Unapproved Executive Share Option Scheme |
1,477,329 |
|
Long Term Incentive Plan |
1,224,399 |
|
Deferred Annual Bonus Scheme |
486,987 |
When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of 5 pence each in the capital of Advanced Medical Solutions Group plc.
It is expected that admission will become effective for the Ordinary Shares on 6 September 2018.
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: 44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer
|
|
|
|
|
|
Consilium Strategic Communications |
Tel: 44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser |
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: 44 (0) 20 7597 5970 |
|
Daniel Adams / Patrick Robb / Gary Clarence |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ALSBUGDIXGXBGIB